Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Xencor, Inc. (NASDAQ:XNCR) has earned an average rating of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $24.8750.

Several research analysts have issued reports on the stock. Truist Financial initiated coverage on shares of Xencor in a report on Monday, November 24th. They set a “buy” rating and a $29.00 price target for the company. Cantor Fitzgerald increased their price objective on shares of Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Royal Bank Of Canada boosted their target price on shares of Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Wedbush reiterated an “outperform” rating and set a $26.00 price target on shares of Xencor in a report on Thursday, November 6th. Finally, Barclays lifted their price objective on Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 73,367 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the transaction, the vice president owned 236,574 shares in the company, valued at $3,718,943.28. The trade was a 23.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the transaction, the chief executive officer directly owned 466,635 shares in the company, valued at approximately $7,330,835.85. This represents a 19.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.76% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xencor

Several hedge funds and other institutional investors have recently bought and sold shares of XNCR. AQR Capital Management LLC acquired a new stake in shares of Xencor in the 1st quarter worth about $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock worth $471,000 after purchasing an additional 3,692 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Xencor by 89.9% in the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock worth $7,732,000 after purchasing an additional 344,088 shares during the last quarter. State of Alaska Department of Revenue raised its stake in shares of Xencor by 9.2% in the second quarter. State of Alaska Department of Revenue now owns 42,351 shares of the biopharmaceutical company’s stock worth $332,000 after purchasing an additional 3,574 shares during the last quarter. Finally, Aberdeen Group plc lifted its holdings in shares of Xencor by 48.2% in the second quarter. Aberdeen Group plc now owns 558,810 shares of the biopharmaceutical company’s stock valued at $4,392,000 after purchasing an additional 181,698 shares in the last quarter.

Xencor Trading Down 3.2%

Shares of XNCR opened at $12.79 on Monday. The stock’s 50-day moving average price is $15.62 and its two-hundred day moving average price is $12.08. Xencor has a 12 month low of $6.92 and a 12 month high of $21.00. The company has a market capitalization of $913.33 million, a PE ratio of -7.23 and a beta of 0.97.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.64. The company had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $29.73 million. Xencor had a negative return on equity of 20.44% and a negative net margin of 87.14%.The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.71) earnings per share. Equities research analysts predict that Xencor will post -3.68 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.